Recent advances in chemotherapy and targeted therapies for breast sarcoma

Ana Dolcan; Daniela A Ferraro; Giovani Dei Tos; Christophe Cisarovsky; Laureline Wetterwald; Ioannis A Voutsadakis; Stephane Cherix; Antonia Digklia

doi:10.1080/14737140.2025.2604619

Back

Recent advances in chemotherapy and targeted therapies for breast sarcoma

Journal article

Peer reviewed

Recent advances in chemotherapy and targeted therapies for breast sarcoma

Ana Dolcan, Daniela A Ferraro, Giovani Dei Tos, Christophe Cisarovsky, Laureline Wetterwald, Ioannis A Voutsadakis, Stephane Cherix and Antonia Digklia

Expert review of anticancer therapy, Vol.26(5), pp.569-584

05/2026

DOI: 10.1080/14737140.2025.2604619

PMID: 41437719

View Online

Abstract

Breast sarcomas (BS) are considerably less prevalent than breast carcinomas. Nevertheless, they are often aggressive, resulting in substantial morbidity and mortality. Despite advances and the introduction of targeted therapies, the treatment continues to rely on cytotoxic chemotherapy. Given their rarity, this review comprehensively examines recent developments in BS therapies and explores how novel treatments may be integrated into the current standard of care. It also highlights emerging trends in adjuvant treatment for localized disease and targeted therapies for specific histologic subtypes in metastatic cases. This review synthesizes recent developments in BS and integrates novel therapies into the existing treatment paradigm. It underscores the heterogeneity among BS subtypes and discusses emerging trends in adjuvant therapies and targeted agents. Current literature was reviewed by a systematic search using PubMed, focusing on high-impact clinical trials, guidelines, and recent reviews published up to January 2025. Although there is a growing understanding of genomic abnormalities associated with specific sarcoma subtypes, this knowledge has yet to be fully applied to personalized treatment strategies. Future research should focus on integrating genomic insights, enhancing trial design to improve patient's outcome. Robust interdisciplinary collaboration - combined with real-world data collection - is critical in improving treatment outcomes.

Chemotherapy

DFSP

targeted therapy

Breast sarcoma

angiosarcoma

phyllodes

immune checkpoint inhibitors

desmoid

Details

Title: Subtitle: Recent advances in chemotherapy and targeted therapies for breast sarcoma
Creators: Ana Dolcan - University of Lausanne
Daniela A Ferraro - University of Lausanne
Giovani Dei Tos - University of Lausanne
Christophe Cisarovsky - University of Lausanne
Laureline Wetterwald - University of Lausanne
Ioannis A Voutsadakis - University of Iowa
Stephane Cherix - University of Lausanne
Antonia Digklia - University of Lausanne
Resource Type: Journal article
Publication Details: Expert review of anticancer therapy, Vol.26(5), pp.569-584
DOI: 10.1080/14737140.2025.2604619
PMID: 41437719
NLM abbreviation: Expert Rev Anticancer Ther
ISSN: 1744-8328
eISSN: 1744-8328
Publisher: Taylor & Francis; ABINGDON
Language: English
Electronic publication date: 12/29/2025
Date published: 05/2026
Academic Unit: Internal Medicine
Record Identifier: 9985096886702771

Metrics

18 Record Views